Participants in the Bozeman Health Clinical Research study have a 50/50 chance of getting either saline solution or a new generation of vaccine.

Active enrollment for a COVID-19 study underway

Bozeman Health Clinical Research becomes part of a global study effort

Scientific lingo is becoming household vernacular while the world grapples with a staggering pandemic. Hope for a vaccine intensifies as numbers climb and experts eye the approaching winter season wearily. Bozeman Health Clinical Research will be a study site for a new investigational vaccine sponsored by Pfizer Inc. and BioNTech SE. – this means that Montanans can help the scientific community confront a thus far indomitable adversary.

The Bozeman study site will be one of more than 120 global clinical investigation sites that will “collectively enroll up to 30,000 participants, nonpregnant adults ages 18-85 year old of any gender, race, and ethnicity. Involving people from all backgrounds is needed to improve the development of this vaccine for everyone,” a Bozeman Health press release stated.

According to Bozeman Health Marketing and Communications Director Lauren Brendel, so far there are 41 active participants in the Bozeman Health Clinical Research study and around another 40 scheduled. Those numbers are changing daily.

Details of the study

This is not the first study in which Bozeman Health Clinical Research has worked with Pfizer.

Eligibility standards must be met by participants and will be assessed via an Informed Consent as well as screening procedures.

Half of the participants will be given placebo – just saline solution.

The other half will receive the mRNA vaccine. A small amount of modified RNA will be injected to the shoulder deltoid muscle.

“This instructs cells to create a very small piece of material that can cause an immune system response. This material or antigen is a bit of protein which is incapable of replicating the virus or causing an individual to contract the COVID-19 virus. The immune system will recognize that protein as not belonging, and begin producing antibodies to it,” the press release said.

The mRNA will gradually be removed by the body’s recycling processes – after it has trained the immune system to fight the virus. Educated immune cells and antibodies provide protection from the actual virus to the individual receiving the vaccine.

Injection site soreness, muscle soreness, and, occasionally, a brief fever could be side effects. Pivotal goals of the study include determining vaccine effectiveness and the duration of that effectiveness.

Participants are being actively enrolled. People interested in participating in the study through the Bozeman Health Clinical Research study site can visit or call 406-414-4475 to find out more.

More Information

Lone Peak Lookout

Cori Koenig, editor:
Susanne Hill, billing:
Ad orders, inserts, classifieds:
Comment Here